ArticleScientific reports2026
Association of ANXA3 methylation with clinical outcomes of glucocorticoid therapy in patients with hepatitis B virus-related acute-on-chronic liver failure.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
There are individual differences in the efficacy of glucocorticoid therapy for hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF). Annexin A3 (ANXA3), as a potential biomarker, may be associated with the clinical outcomes of glucocorticoid therapy in HBV-ACLF patients. We enrolled 108 HBV-ACLF patients receiving glucocorticoid therapy to assess the effects of glucocorticoid therapy on ANXA3 mRNA and methylation levels in peripheral blood mononuclear cells. At the same time, clinical parameters during therapy were collected. In HBV-ACLF patients who survived, ANXA3 expression significantly decreased after glucocorticoid therapy, while methylation levels increased. No significant changes were observed in non-survivors. Logistic regression analysis of 90-day follow-up further indicated that ANXA3 methylation levels could serve as an independent predictor of glucocorticoid treatment response, with its elevation significantly correlating with favorable clinical outcomes. In HBV-ACLF patients, ANXA3 methylation levels were associated with clinical outcomes following glucocorticoid therapy, suggesting its potential as a candidate therapy-associated prognostic biomarker.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.